🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

T6A Biomarker for Detection of Bacterial Infection in Newborn Infants

Recruitingn/aAges any - anyAllSalzburger Landeskliniken
NCT07670624 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This bi-center study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Newborn infants who require blood testing for screening for bacterial infection OR treating physician suspects bacterial infection in newborn infant * Signed informed consent form Exclusion Criteria: 1. Refusal to participate in study or not providing written informed consent by caregivers/parents 2. Antibiotic treatment of any kind.
💊

What it tests

  • Not listed
📍

Where

2 sites
Paracelsus Medical Private University- University Hospital Salzburg Dept. of Pediatrics and Adolescent Medicine, Division of Neonatology
Salzburg, Austria
Wroclaw Medical University
Wroclaw, Poland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy